Format

Send to

Choose Destination
J Pain Res. 2018 Oct 8;11:2221-2227. doi: 10.2147/JPR.S152216. eCollection 2018.

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice.

Author information

1
UCSD Center for Pain Medicine, La Jolla, CA, USA, Jessica.OswaldEM@gmail.com.

Abstract

Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the vasoconstriction associated with triptans limit their use in patients with pre-existing cardiovascular risk factors. Preferential 5-HT1F agonists have shown promising results in in vitro and early proof-of-concept trials. Lasmiditan, a highly selective 5-HT1F agonist, has completed two Phase III randomized, double blind, placebo-controlled clinical trials, with a third - a long-term, open-label safety study - still underway. Research to date suggests lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment option in patients refractory to current acute migraine medications or who have cardiovascular risk factors.

KEYWORDS:

5HT-1F; headache; lasmiditan; migraine; serotonin

Conflict of interest statement

Disclosure Nathaniel M Schuster has a research collaboration with Eli Lilly & Co. not related to lasmiditan. The authors have not received funding for the generation of this manuscript. The authors report no conflicts of interest in this work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center